文献速递胸部肿瘤

阿替利珠单抗联合同步放化疗治疗不可切除NSCLC的II期试验

Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC.
PubMed 文献 · J Thorac Oncol · 2019-11-25

该II期研究分两部分:第一部分(n=10)为常规分割放化疗后巩固化疗联合阿替利珠单抗及维持治疗;第二部分(n=30)为同步放化疗联合阿替利珠单抗后相同巩固和维持治疗。结果显示两部分3级及以上不良事件均为80%,免疫相关3级及以上不良事件分别为30%和20%,≥2级肺炎分别为10%和16%;第二部分中位随访15.1个月,中位无进展生存期13.2个月,总生存期未达到;无论PD-L1状态如何,复发无差异。结论认为阿替利珠单抗联合同步放化疗安全可行,与历史率相比未增加毒性。

要点

  • 同步阿替利珠单抗联合放化疗安全可行,未增加毒性。
  • 第二部分中位PFS为13.2个月,总生存未达到。
  • 无论PD-L1状态如何,复发无差异。

核心结论

  • 阿替利珠单抗联合同步放化疗安全可行,与历史率相比未增加毒性。

研究设计与样本

  • II期研究分两部分:第一部分n=10,常规分割放化疗后巩固化疗联合阿替利珠单抗及维持治疗;第二部分n=30,同步放化疗联合阿替利珠单抗后相同巩固和维持治疗。

主要发现

  • 第一部分3级及以上不良事件80%,免疫相关3级及以上30%,≥2级肺炎10%。
  • 第二部分3级及以上不良事件80%,免疫相关3级及以上20%,≥2级肺炎16%。
  • 第一部分中位随访22.5个月,中位PFS 18.6个月,OS 22.8个月。
  • 第二部分中位随访15.1个月,中位PFS 13.2个月,OS未达到。
  • 无论PD-L1状态如何,复发无差异。

临床怎么用

  • 对于不可切除局部晚期NSCLC,可考虑同步阿替利珠单抗联合放化疗,但需注意免疫相关不良反应和肺炎监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Consolidation durvalumab after chemoradiation (CRT) is the current standard of care for locally advanced NSCLC. We hypothesized that adding immunotherapy concurrently with CRT (cCRT) would increase efficacy without additive toxicity. METHODS: This phase II study was conducted in two parts. Part 1 (n = 10) involved administration of conventionally fractionated CRT followed by consolidation chemotherapy (atezolizumab [two cycles] and maintenance atezolizumab up to 1 y). Part 2 (n = 30) involved administration of cCRT with atezolizumab followed by the same consolidation and maintenance therapies as in part 1. Programmed cell death ligand-1 staining cutoffs (1% or 50%) using Dako 22C3 immunohistochemistry were correlated with clinical outcomes. RESULTS: The overall toxicities for part 1/2 were overall adverse events of grade 3 and above of 80%/80%; immune-related adverse events of grade 3 and above of 30%/20%; and pneumonitis of grade 2 and above of 10%/16%, respectively. In part 1, for preliminary efficacy results, with a median follow-up of 22.5 months, the median progression-free survival was 18.6 months, and the overall survival was 22.8 months. In part 2, with a median follow-up time of 15.1 months, the median progression-free survival was 13.2 months, and the overall survival was not reached. There was no difference in cancer recurrence regardless of programmed cell death ligand-1 status. CONCLUSIONS: Atezolizumab with cCRT is safe and feasible and has no added toxicities compared with historical rates.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Lin SH, Lin Y, Yao L, et al. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2019. PMID: 31778797. doi:10.1016/j.jtho.2019.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。